OncLive TV

OncLive® TV is an editorial video program featuring one-on-one live and/or virtual interviews with key opinion leaders in the oncology field for their expert insight on breaking news, regulatory updates, practice-changing data presented at medical meetings, and other pivotal topics in a cancer specialty, including breast cancer, lung cancer, genitourinary cancers, gastrointestinal cancers, gynecologic cancers, and hematologic cancers.

Dr. Agarwal on Developing Biomarkers of Response to Cabozantinib/Atezolizumab in mCRPC

February 27th 2020

Neeraj Agarwal, MD, discusses the importance of developing biomarkers of response to the combination of cabozantinib and atezolizumab in patients with metastatic castration-resistant prostate cancer.

Dr. Graff on Results of the KEYNOTE-199 Trial in mCRPC

February 27th 2020

Julie N. Graff, MD, discusses the results of the phase II KEYNOTE-199 trial in metastatic castration-resistant prostate cancer.

Dr. Oh on Remaining Challenges With Prostate Cancer Treatment

February 27th 2020

William K. Oh, MD, discusses remaining challenges with the advancing treatments in prostate cancer.

Dr. Grivas on Comparisons Between ATM and BRCA1/2 Mutations in mCRPC

February 27th 2020

Petros Grivas, MD, discusses comparisons between ATM and BRCA1/2 mutations in metastatic castration-resistant prostate cancer.

Dr. Snyder on Transplant Updates in Myelofibrosis

February 26th 2020

David S. Snyder, MD, discusses updates in treating patients with myelofibrosis who undergo transplant.

Dr. Kuykendall on the Approval of Fedratinib in Myelofibrosis

February 26th 2020

Andrew T. Kuykendall, MD, discusses the additionof fedratinib to the treatment paradigm in myelofibrosis.

Dr. Garcia on the Tolerability of Navitoclax/Ruxolitinib in Myelofibrosis

February 26th 2020

Jacqueline S. Garcia, MD, discusses the tolerability of the combination of navitoclax plus ruxolitinib in patients with myelofibrosis.

Dr. Goldman on Targeted Therapy Options for EGFR-, ALK-, and ROS1-Mutated NSCLC

February 26th 2020

Jonathan W. Goldman, MD, discusses targeted therapy options for patients with EGFR-, ALK-, and ROS1-mutated non–small cell lung cancer.

Dr. Wolpin on the CCGA Study of Blood-Based Testing for Early Detection of GI Cancers

February 26th 2020

Brian M. Wolpin, MD, MPH, discusses the GI subgroup findings of the Circulating Cell-Free Genome Atlas study.

Dr. Brahmer on Targeting Driver Mutations in NSCLC

February 26th 2020

Julie R. Brahmer, MD, discusses targeted treatments for patients with oncogene-driven non–small cell lung cancer.

Dr. Daver on Azacitidine and Nivolumab in Acute Myeloid Leukemia

February 26th 2020

Naval G. Daver, MD, discusses the rationale of azacitidine and nivolumab in acute myeloid leukemia.

Dr. Blum on the Current Treatment Landscape of Acute Myeloid Leukemia

February 26th 2020

William G. Blum, MD, discusses the current treatment landscape of acute myeloid leukemia.

Dr. Penson on the Eligibility Criteria for PARP Inhibitors in Advanced Ovarian Cancer

February 26th 2020

Richard T. Penson, MD, MRCP, associate professor of medicine, Harvard Medical School, and clinical director of Medical Gynecologic Oncology, in the Department of Medicine, Massachusetts General Hospital, discusses the eligibility criteria for PARP inhibitors in advanced ovarian cancer.

Dr. Hoffman on Research Regarding Neoadjuvant Chemo and Primary Debulking in Ovarian Cancer

February 26th 2020

Mitchel Hoffman, MD, gynecologic oncologist, Moffitt Cancer Center, discusses ongoing research regarding neoadjuvant chemotherapy and primary debulking surgery in advanced ovarian cancer.

Dr. Wenham on Trials Evaluating IP, IV, and Dose-Dense Chemotherapy in Ovarian Cancer

February 26th 2020

Robert M. Wenham, MD, gynecologic oncologist and chair of the Gynecologic Oncology Program at Moffitt Cancer Center, discusses data with intraperitoneal (IP) chemotherapy, dose-dense chemotherapy, and intravenous (IV) chemotherapy in patients with advanced ovarian cancer.

Dr. Beltran on Use of ctDNA to Evaluate Treatment Resistance in Prostate Cancer

February 25th 2020

Himisha Beltran, MD, associate professor of medicine, Lank Center for Genitourinary Oncology, Division of Molecular and Cellular Oncology, Harvard Medical School, director of Translational Research, and physician, Dana-Farber Cancer Institute, discusses the potential use of circulating tumor DNA to detect castration-resistant neuroendocrine prostate cancer.

Dr. Gerds on Luspatercept to Treat Anemia in Myelofibrosis

February 25th 2020

Aaron Gerds, MD, discusses results of a phase II trial examining the safety and efficacy of luspatercept as a treatment for anemia in patients with myelofibrosis.

Dr. Mesa on the Safety Profiles of JAK Inhibitors in Myelofibrosis

February 25th 2020

Ruben Mesa, MD, discusses the adverse events of ruxolitinib and fedratinib in myelofibrosis.

Dr. Jain on Challenges With Allogeneic Transplant in Myelofibrosis

February 25th 2020

Tania Jain, MBBS, discusses the challenges with allogeneic transplant in patients with myelofibrosis.

Dr. Copeland on the Prevalence of Ovarian Cancer in the United States

February 25th 2020

Larry J. Copeland, MD, discusses the prevalence of ovarian cancer in the United States.